JAK
JAK (Janus kinase) inhibitors are compounds that target the JAK-STAT signaling pathway, which is involved in cell growth, immune response, and angiogenesis. By inhibiting JAK, these compounds can reduce the signaling that leads to the formation of new blood vessels in tumors, thereby inhibiting tumor growth. JAK inhibitors are important in the treatment of cancers and inflammatory diseases. At CymitQuimica, we offer a diverse range of high-quality JAK inhibitors to support your research in oncology, immunology, and angiogenesis.
Products of "JAK"
Sort by
GLPG0634 analog
CAS:GLPG0634 analog (GLPG0634 analogue) is a specific JAK1 inhibitor with IC50 of 10/28/810/116 nM for JAK1/2/3 and TYK2, respectively.Formula:C23H18N6O2Purity:100% - 99.22%Color and Shape:SolidMolecular weight:410.43Ref: TM-T3076
1mg40.00€2mg52.00€5mg88.00€10mg144.00€25mg264.00€50mg465.00€100mg658.00€500mg1,378.00€1mL*10mM (DMSO)87.00€XL019
CAS:XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.Formula:C25H28N6O2Purity:99.19%Color and Shape:SolidMolecular weight:444.53WP1066
CAS:WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.Formula:C17H14BrN3OPurity:98.92% - 99.73%Color and Shape:SolidMolecular weight:356.22SC99
CAS:SC99 inhibits JAK2-STAT3, reducing STAT3 genes, platelet activity, and has anti-myeloma, anti-thrombotic effects.Formula:C15H8Cl2FN3OPurity:99.56%Color and Shape:SolidMolecular weight:336.15Ref: TM-T8719
1mg46.00€5mg93.00€10mg140.00€25mg240.00€50mg363.00€100mg452.00€200mg630.00€1mL*10mM (DMSO)99.00€SAR-20347
CAS:SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).Formula:C21H18ClFN4O4Purity:99.35% - 99.77%Color and Shape:SolidMolecular weight:444.84Ref: TM-T4210
1mg35.00€5mg80.00€10mg116.00€25mg227.00€50mg354.00€100mg588.00€200mg818.00€1mL*10mM (DMSO)88.00€BMS-911543
CAS:BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.Formula:C23H28N8OPurity:97.69% - 99.98%Color and Shape:SolidMolecular weight:432.52Decernotinib
CAS:Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.Formula:C18H19F3N6OPurity:100% - 99.45%Color and Shape:SolidMolecular weight:392.38Ref: TM-T2636
1mg38.00€2mg52.00€5mg79.00€10mg110.00€25mg217.00€50mg329.00€100mg494.00€200mg705.00€1mL*10mM (DMSO)88.00€CHZ868
CAS:CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.Formula:C22H19F2N5O2Purity:99.38%Color and Shape:SolidMolecular weight:423.42Milpecitinib
CAS:Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.Formula:C20H20N4O2SColor and Shape:SolidMolecular weight:380.463Ilginatinib
CAS:Ilginatinib (NS-018) is a highly active and orally bioavailable inhibitor of JAK2.Formula:C21H20FN7Purity:98.40% - 99.01%Color and Shape:SolidMolecular weight:389.43Ref: TM-T12266
1mg64.00€5mg138.00€10mg187.00€25mg273.00€50mg393.00€100mg562.00€200mg743.00€1mL*10mM (DMSO)133.00€JANEX-1
CAS:JANEX-1: cell-permeable, reversible Jak3 inhibitor (IC50: 78 μM), ATP-competitive, selective; weak on JAK1/2, Zap/Syk, SRC.Formula:C16H15N3O3Purity:98% - 99.73%Color and Shape:SolidMolecular weight:297.31Ref: TM-T2045
1mg44.00€2mg55.00€5mg92.00€10mg150.00€25mg248.00€50mg444.00€100mg652.00€500mg1,378.00€1mL*10mM (DMSO)92.00€MM-589
CAS:MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.Formula:C28H44N8O5Purity:98%Color and Shape:SolidMolecular weight:572.70Povorcitinib phosphate
CAS:Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.Formula:C23H25F5N7O5PPurity:97.71%Color and Shape:SolidMolecular weight:605.45Ref: TM-T39113L
1mg65.00€2mg95.00€5mg145.00€10mg212.00€25mg359.00€50mg512.00€100mg695.00€200mg937.00€JAK-IN-33
JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].Purity:98%Color and Shape:Odour SolidPeficitinib
CAS:Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.Formula:C18H22N4O2Purity:98.67% - 99.4%Color and Shape:SolidMolecular weight:326.39Ref: TM-T6933
2mg40.00€5mg66.00€10mg104.00€25mg182.00€50mg283.00€100mg439.00€200mg645.00€1mL*10mM (DMSO)73.00€FLLL32
CAS:FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).Formula:C28H32O6Purity:96.39% - 97.90%Color and Shape:SolidMolecular weight:464.55Ref: TM-T6838
2mg46.00€5mg66.00€10mg93.00€25mg124.00€50mg197.00€100mg350.00€500mg840.00€1mL*10mM (DMSO)72.00€Cerdulatinib hydrochloride
CAS:Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.Formula:C20H28ClN7O3SPurity:99.23%Color and Shape:SolidMolecular weight:482Ifidancitinib
CAS:Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.Formula:C20H18FN5O3Purity:98.05%Color and Shape:SolidMolecular weight:395.39JAK-IN-10
CAS:JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.Formula:C20H18FN5O3SPurity:98.88%Color and Shape:SolidMolecular weight:427.45Ref: TM-T13571
1mg87.00€5mg177.00€10mg260.00€25mg429.00€50mg605.00€100mg815.00€500mg1,624.00€1mL*10mM (DMSO)188.00€Cerdulatinib
CAS:Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor.Formula:C20H27N7O3SPurity:98.74% - 99.49%Color and Shape:SolidMolecular weight:445.54Ref: TM-T2487
1mg44.00€2mg55.00€5mg79.00€10mg106.00€25mg185.00€50mg283.00€100mg432.00€200mg605.00€500mg938.00€1mL*10mM (DMSO)86.00€Tofacitinib Citrate
CAS:Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).Formula:C22H28N6O8Purity:99.19% - 99.75%Color and Shape:SolidMolecular weight:504.49TAK-901
CAS:TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among othersFormula:C28H32N4O3SPurity:97.38% - 99.1%Color and Shape:SolidMolecular weight:504.64Brevilin A
CAS:Brevilin A, a sesquiterpene from Centipeda minima, hinders JAK and blocks STAT3 (IC50=10.6μM), inducing apoptosis and autophagy in cancer cells.Formula:C20H26O5Purity:100% - 99.74%Color and Shape:SolidMolecular weight:346.42Ref: TM-T4672
1mg96.00€5mg215.00€10mg369.00€25mg610.00€50mg840.00€100mg1,130.00€500mg2,308.00€1mL*10mM (DMSO)235.00€Ilginatinib hydrochloride
CAS:Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.Formula:C21H21ClFN7Purity:99.55%Color and Shape:SolidMolecular weight:425.89Ref: TM-T12266L2
1mg77.00€5mg165.00€10mg240.00€25mg408.00€50mg562.00€100mg800.00€200mg1,074.00€1mL*10mM (DMSO)177.00€2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS:2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.Formula:C16H13Cl2N3O2Purity:98.77%Color and Shape:SolidMolecular weight:350.2JAK-IN-5 hydrochloride
CAS:JAK-IN-5 hydrochloride is a JAK inhibitor [1].Formula:C27H32ClFN6OColor and Shape:SolidMolecular weight:511.03JAK3-IN-6
CAS:JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nMFormula:C19H18N4O3Purity:97.46% - 99.94%Color and Shape:SolidMolecular weight:350.37Cenacitinib
CAS:Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.Formula:C19H19F2N7O3Color and Shape:SolidMolecular weight:431.40JAK/HDAC-IN-2
JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations.Formula:C28H38N6O5SPurity:98%Color and Shape:SolidMolecular weight:570.7Nimucitinib
CAS:Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.Formula:C25H26F2N6O2Purity:98.71%Color and Shape:SoildMolecular weight:480.51Ref: TM-T67907
1mg96.00€2mg139.00€5mg227.00€10mg354.00€25mg653.00€50mg938.00€100mg1,454.00€500mg2,822.00€JAK2-IN-6
CAS:JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.Formula:C14H10ClN3OS2Purity:99.38%Color and Shape:SolidMolecular weight:335.83JAK3 covalent inhibitor-1
CAS:JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM andFormula:C22H17FN6O2SPurity:98%Color and Shape:SolidMolecular weight:448.47Brepocitinib P-Tosylate
CAS:Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).Formula:C25H29F2N7O4SPurity:99.82% - 99.97%Color and Shape:SolidMolecular weight:561.6Dual Cathepsin L/JAK-IN-1
CAS:DualCathepsinL/JAK-IN-1 (Compound A8) serves as a dual inhibitor of Cathepsin L (CTSL) and JAK, exhibiting IC50 values of 0.68 μM for CTSL and 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for JAK1/2/3 and TYK2, respectively. This compound effectively prevents the activation of MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. DualCathepsinL/JAK-IN-1 is applicable in research on acute lung injury (ALI).Formula:C19H18ClN5Color and Shape:SolidMolecular weight:351.833Jaspamycin
CAS:Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.Formula:C12H12N4O5Color and Shape:SolidMolecular weight:292.25AT9283
CAS:AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).Formula:C19H23N7O2Purity:99.83% - 99.98%Color and Shape:SolidMolecular weight:381.43Ref: TM-T3068
1mg47.00€2mg60.00€5mg95.00€10mg170.00€25mg299.00€50mg499.00€100mg723.00€1mL*10mM (DMSO)97.00€Pacritinib
CAS:Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays).Formula:C28H32N4O3Purity:99.25% - 99.49%Color and Shape:SolidMolecular weight:472.58Upadacitinib
CAS:Upadacitinib (ABT-494), a selective JAK1 inhibitor, is researched for autoimmune diseases; IC50: 43 nM.Formula:C17H19F3N6OPurity:98.96% - 99.93%Color and Shape:SolidMolecular weight:380.37Ref: TM-T7503
1mg47.00€2mg62.00€5mg89.00€10mg130.00€25mg220.00€50mg306.00€100mg434.00€200mg662.00€500mg1,169.00€1mL*10mM (DMSO)48.00€Gandotinib
CAS:LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).Formula:C23H25ClFN7OPurity:99.33% - 99.86%Color and Shape:SolidMolecular weight:469.94Ref: TM-T2638
5mg51.00€10mg88.00€25mg160.00€50mg296.00€100mg469.00€500mg1,035.00€1mL*10mM (DMSO)57.00€JAK2-IN-7
CAS:JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.Formula:C26H33N7OPurity:98.71%Color and Shape:SolidMolecular weight:459.59Ref: TM-T35900
1mg145.00€5mg354.00€10mg630.00€25mg1,301.00€50mg1,738.00€100mg2,357.00€1mL*10mM (DMSO)358.00€AZ-3
CAS:AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).Formula:C20H28FN7Purity:98%Color and Shape:SolidMolecular weight:385.48JAK-IN-28
CAS:JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].Formula:C20H18ClN7OPurity:98%Color and Shape:SolidMolecular weight:407.86JBJ-04-125-02
CAS:JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.Formula:C29H26FN5O3SPurity:98%Color and Shape:SolidMolecular weight:543.61JAK3-IN-7
CAS:JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction afterFormula:C17H20N6OPurity:98.81%Color and Shape:SolidMolecular weight:324.38Tyrphostin AG 490
CAS:Formula:C17H14N2O3Purity:>98.0%(T)(HPLC)Color and Shape:White to Light yellow powder to crystalMolecular weight:294.31DTP3
CAS:DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.Formula:C26H35N7O5Color and Shape:SolidMolecular weight:525.6Pumecitinib
CAS:Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.Formula:C17H20N8O2SPurity:99.89%Color and Shape:SoildMolecular weight:400.46RGB-286638 free base
CAS:RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.Formula:C29H35N7O4Purity:97.29% - 99.91%Color and Shape:SolidMolecular weight:545.63Fosifidancitinib
CAS:Fosifidancitinib is a potent inhibitor of JAK 1 and JAK 3.Formula:C21H21FN5O7PPurity:99.55%Color and Shape:SolidMolecular weight:505.39Ref: TM-T38624
1mg87.00€2mg124.00€5mg187.00€10mg284.00€25mg452.00€50mg645.00€100mg867.00€200mg1,159.00€STAT3-IN-18
CAS:STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells andFormula:C18H24Cl2N2O6PtPurity:98%Color and Shape:SolidMolecular weight:630.38
